These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36409061)

  • 21. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?
    Williams DR; Lees AJ
    Mov Disord; 2010 Feb; 25(3):357-62. PubMed ID: 20108379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PSP as distinguished from CBD, MSA-P and PD by clinical and imaging differences at an early stage.
    Kurata T; Kametaka S; Ohta Y; Morimoto N; Deguchi S; Deguchi K; Ikeda Y; Takao Y; Ohta T; Manabe Y; Sato S; Abe K
    Intern Med; 2011; 50(22):2775-81. PubMed ID: 22082889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration.
    Fabbrini G; Fabbrini A; Suppa A
    Handb Clin Neurol; 2019; 165():155-177. PubMed ID: 31727210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Electrophysiological and clinical assessment of dysautonomia in multiple system atrophy (MSA) and progressive supranuclear palsy (PSP): a comparative study.
    Nojszewska M; Potulska-Chromik A; Jamrozik Z; Janik P; Zakrzewska-Pniewska B
    Neurol Neurochir Pol; 2019; 53(1):26-33. PubMed ID: 30620042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau-PET and multimodal imaging in clinically atypical multiple system atrophy masquerading as progressive supranuclear palsy.
    Carlos AF; Sekiya H; Koga S; Pham NTT; Ali F; Botha H; Clark HM; Coon EA; Lowe V; Ahlskog JE; Trejo-Lopez JA; Dickson DW; Whitwell JL; Josephs KA
    Parkinsonism Relat Disord; 2022 Aug; 101():9-14. PubMed ID: 35752126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank.
    Koga S; Cheshire WP; Tipton PW; Driver-Dunckley ED; Wszolek ZK; Uitti RJ; Graff-Radford NR; van Gerpen JA; Dickson DW
    Parkinsonism Relat Disord; 2021 Aug; 89():155-161. PubMed ID: 34303202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypodipsia discriminates progressive supranuclear palsy from other parkinsonian syndromes.
    Stamelou M; Christ H; Reuss A; Oertel W; Höglinger G
    Mov Disord; 2011 Apr; 26(5):901-5. PubMed ID: 21384428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonmotor Features in Atypical Parkinsonism.
    Bhatia KP; Stamelou M
    Int Rev Neurobiol; 2017; 134():1285-1301. PubMed ID: 28805573
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contribution of trigemino-cervical reflexes in distinguishing progressive supranuclear palsy from multiple system atrophy.
    Serrao M; Di Fabio R; Bartolo M; Perrotta A; Tassorelli C; Coppola G; Davassi C; Padua L; Sandrini G; Pierelli F
    Clin Neurophysiol; 2011 Sep; 122(9):1812-5. PubMed ID: 21396886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The odor stick identification test for Japanese differentiates Parkinson's disease from multiple system atrophy and progressive supra nuclear palsy.
    Suzuki M; Hashimoto M; Yoshioka M; Murakami M; Kawasaki K; Urashima M
    BMC Neurol; 2011 Dec; 11():157. PubMed ID: 22192419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.
    Ali F; Martin PR; Botha H; Ahlskog JE; Bower JH; Masumoto JY; Maraganore D; Hassan A; Eggers S; Boeve BF; Knopman DS; Drubach D; Petersen RC; Dunkley ED; van Gerpen J; Uitti R; Whitwell JL; Dickson DW; Josephs KA
    Mov Disord; 2019 Aug; 34(8):1144-1153. PubMed ID: 30726566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy.
    Seppi K; Schocke MF; Esterhammer R; Kremser C; Brenneis C; Mueller J; Boesch S; Jaschke W; Poewe W; Wenning GK
    Neurology; 2003 Mar; 60(6):922-7. PubMed ID: 12654954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.
    Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH
    J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcomes of two main variants of progressive supranuclear palsy and multiple system atrophy: a prospective natural history study.
    Jecmenica-Lukic M; Petrovic IN; Pekmezovic T; Kostic VS
    J Neurol; 2014 Aug; 261(8):1575-83. PubMed ID: 24888315
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentiation of progressive supranuclear palsy: clinical, imaging and laboratory tools.
    Liscic RM; Srulijes K; Gröger A; Maetzler W; Berg D
    Acta Neurol Scand; 2013 May; 127(5):362-70. PubMed ID: 23406296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of gray matter atrophy in atypical parkinsonism syndromes: a VBM meta-analysis.
    Yu F; Barron DS; Tantiwongkosi B; Fox P
    Brain Behav; 2015 Jun; 5(6):e00329. PubMed ID: 26085961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers.
    Mangesius S; Mariotto S; Ferrari S; Pereverzyev S; Lerchner H; Haider L; Gizewski ER; Wenning G; Seppi K; Reindl M; Poewe W
    Parkinsonism Relat Disord; 2020 Aug; 77():57-63. PubMed ID: 32622301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias.
    Stamelou M; Diehl-Schmid J; Hapfelmeier A; Kontaxopoulou D; Stefanis L; Oertel WH; Bhatia KP; Papageorgiou SG; Höglinger GU
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1264-8. PubMed ID: 26324212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics of Multiple System Atrophy and Progressive Supranuclear Palsy: A Systemized Review of the Literature.
    Bougea A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.
    Bensimon G; Ludolph A; Agid Y; Vidailhet M; Payan C; Leigh PN;
    Brain; 2009 Jan; 132(Pt 1):156-71. PubMed ID: 19029129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.